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generally did not contribute to explaining the magnitude
of change achieved by the patients. However, the number
of hours of supervised exercise (HREX, 25.4 hr ± 9.2)
did contribute to explaining increases in 5 of the 8 SF-36
domains: physical function (p = 0.027), physical role
(p = 0.0002), health perceptions (p = 0.0167), vitality
(p = 0.034), and social function (p = 0.0035).
CONCLUSION: These data suggest that outcomes spe-
cifically related to pulmonary diseases are not affected by
a longer duration for this type of intervention, but that
broader, population-based assessments may need an ad-
ditional period of intervention, or elapsed time, to detect
improvement.
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OBJECTIVES: To determine the relative cost-effective-
ness of the inhaled corticosteroids beclomethasone dipro-
pion ate (BDP), budesonide (BUD), and fluticasone propi-
onate (FP), for managing moderate to severe asthma in
adults over a one-year time horizon from the perspective
of the Ministry of Health (MOH) in Canada.
METHODS: A single-arm meta-analysis of randomized
control trials containing at least one of FP, BUD, and BDP
was performed in order to derive estimates of effectiveness
and tolerance. A decision tree analysis was then used to
model the cost-effectiveness analysis. Only direct medical
costs were included in the analysis (i.e., inpatient care,
emergency visits, physician services, nursing services,
drugs, diagnostic tests). The time horizon of the study was
52 weeks, precluding discounting. All costs are presented
in 1996 Canadian dollars (CDN$). The cost-effectiveness
was the cost per additional symptom-free day ($/SFD).
RESULTS: 69 of 398 articles were included in the meta-
analysis. The Monte Carlo base case analysis showed that
FP and BUD resulted in an annual cost of $1,383 and
$1,147 respectively (p < 0.01). FP produced 216 SFDs
while BUD resulted in 214 SFDs, which were not signifi-
cantly different at p = 0.01 (corrected for multiple com-
parisons). BDP cost $1,343/year and yielded 213 SFD/
year (BDP was excluded from the final analysis, domi-
nated by BUD). With no difference in effectiveness, a
cost-minimization analysis showed that BUD was the
cost-effective alternative, costing $236 CDN less than the
FP strategy.
CONCLUSIONS: Of the inhaled corticosteroids avail-
able on the MOH Formulary in Canada, BUD is a cost-
effective alternative for the treatment of adults with mod-
erate to severe asthma.
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The Veterans Health Administration awarded national pur-
chasing contracts for the H2RAs to cimetidine and famoti-
dine. Our patients were taking ranitidine but were switched
to one of the two contracted agents. The conversion process
was performed by a pharmacist via local protocol. Patients
were contacted by phone and mailed a handout explaining
the rationale for the medication switch.
OBJECTIVES: To evaluate how patients feel concerning
their new H2RA and the way we informed them of the
conversion.
METHODS: In this cross-sectional study, a "generic drug
conversion" patient satisfaction questionnaire was mailed
to 295 patients converted to either cimetidine (53 pa-
tients) or famotidine (242 patients).
RESULTS: There were 181 returned questionnaires, a
61.3% total response rate. Patient responses were as fol-
lows: 69.4% answered that their new H2RA works the
same or better than ranitidine; 16.4% answered that their
new H2RA had more side effects/problems than raniti-
dine; 80.4% answered that the conversion process was
clearly explained to them; 13.3% of patients contacted
the VA concerning their new H2RA medication; 76.4%
answered that the way they were informed of the conver-
sion was good to excellent. The only difference found, af-
ter subgroup analysis, was that 48.2 % of the cimetidine
patients subjectively rated it to work worse than raniti-
dine, versus 27.1 % of the famotidine patients, using their
own criteria (Chi-square, p < 0.028; OR 2.51).
CONCLUSIONS: The data suggest that the majority of the
patients believe their new H2RA works well for them and
are satisfied with the conversion process. Of the patients
who rated their new H2RA to work worse than ranitidine,
there is a 2.51 times greater chance that they were taking ci-
metidine as compared to patients whose H2RA worked
worse than ranitidine and were taking famotidine.
